Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636206 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
NCT01636206: Completed Phase 3 study, sponsored by Shire.
NCT01636206 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 332 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01636206, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.
Interventions
- DRUG Placebo
- DRUG Lifitegrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2012-10-16 |
| Est. Completion | 2014-03-03 |
| Phase | Phase 3 |
What the finished NCT01636206 record still lists
NCT01636206 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01636206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01636206 about?
NCT01636206 is a clinical study titled "Safety Study of Lifitegrast to Treat Dry Eye". The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.
What is the current status of trial NCT01636206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2012-10-16. Estimated completion is 2014-03-03.
What interventions are being tested in trial NCT01636206?
The interventions under investigation include: Placebo (DRUG), Lifitegrast (DRUG).
Who is sponsoring clinical trial NCT01636206?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01636206's enrollment target sits among peer trials
332 1061st of 2000 higher than 935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI